Kejun Pharma secures hundreds of millions in Series B funding led by TaiKun Fund to accelerate the development of innovative antiviral therapies.
Target Information
Kejun Pharma, an innovative company specializing in the research and development of small-molecule antiviral drugs, has successfully completed a Series B funding round amounting to hundreds of millions. This round was led by TaiKun Fund, a subsidiary of Tailong Investment, with significant participation from investors such as Lichen Investment, Taiyu Investment, and continued support from existing shareholders including Honghai Chuangjian and Hankan Capital.
Since its inception, Kejun Pharma has been committed to building advanced targeted prodrug technology and nucleic acid drug platforms. The company has achieved significant progress in the fields of small-molecule and nucleic acid drugs and is accelerating the global clinical development of the next-generation antiplatelet and antiviral drugs.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview
The pharmaceutical industry in China has been experiencing rapid growth, driven by increasing healthcare demands and government support for drug innovation. The focus on biotechnology and pharmaceuticals has intensified as the governm
Similar Deals
泰鲲基金
invested in
柯君医药
in 2025
in a Series B deal